文献速递淋巴瘤

青少年和青年霍奇金淋巴瘤的当前考量

Current considerations in AYA Hodgkin lymphoma.
PubMed 文献 · Br J Haematol · 2018-11-20

霍奇金淋巴瘤常见于青少年和青年(AYA,美国国家癌症研究所定义为15至39岁确诊癌症者),但该人群的治疗获益增量低于儿童和成人患者。本文综述儿童与成人霍奇金淋巴瘤的预后与治疗策略,并强调AYA患者管理中的复杂性。

要点

  • AYA霍奇金淋巴瘤患者治疗获益增量低于儿童和成人患者。
  • AYA患者管理缺乏明确共识,尤其是儿童方案与成人方案的选择。
  • 疾病生物学差异、延迟诊断、临床试验参与减少和治疗依从性受复杂社会因素影响可能是 contributing factors。

核心结论

  • 霍奇金淋巴瘤仍高度可治愈,但AYA患者管理缺乏明确共识,尤其是儿童方案与成人方案的选择及如何整合新兴治疗进展。
  • 需要持续临床试验和协作努力以满足该人群需求、研究独特生物学因素并优化治疗。

研究设计与样本

  • 综述,总结儿童与成人霍奇金淋巴瘤的当前预后与治疗策略。

主要发现

  • AYA人群治疗获益增量低于儿童和成人患者。
  • 确切病因不明,贡献因素可能包括疾病生物学差异、延迟诊断、临床试验参与减少和治疗依从性受复杂社会因素影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hodgkin lymphoma (HL) commonly occurs in adolescents and young adults (AYA), defined by the National Cancer Institute as people diagnosed with cancer between the ages of 15 and 39 years. Despite therapeutic advances, the AYA population has derived less incremental benefit compared to both paediatric and adult counterparts. Although the exact aetiology is unclear, contributing factors probably include differences in disease biology, delayed diagnosis, decreased participation in clinical trials and treatment adherence secondary to complex social factors. As such, while HL remains highly curable, there is not a clear consensus regarding the management of patients within this age range, specifically whether paediatric or adult regimens are preferred or how best to incorporate emerging therapeutic advancements. Ongoing clinical trials, as well as continued collaborative efforts are required to address the needs of this population, investigate the potential for unique biological factors and allow for optimization of treatment. Here we review current prognostic and treatment strategies for paediatric and adult patients with HL and highlight complexities around the management of this patient population.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Crombie JL, LaCasce AS. Current considerations in AYA Hodgkin lymphoma. Br J Haematol. 2018. PMID: 30460695. doi:10.1111/bjh.15640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。